NCCN 2023 Oncology Fellows Program: New Horizons in Quality Cancer Care

March 30, 2023

Designed specifically for oncology fellows, this half-day, CE-certified program seeks to educate future oncology practitioners about the application of the NCCN Guidelines®, evidence-based treatment principles for the management of significant cancer types, the implementation of supportive care in oncology, and recommendations for professional career development.

Target Audience

This program is designed to meet the educational needs of second- and third-year medical, surgical, and radiation oncology fellows.

Learning Objectives

The goal of this program is to ensure that oncology fellows, as members of the interprofessional oncology care team, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with cancer.

Following this program, participants should be able to:

Global Learning Objectives
•   Evaluate advances in the management of patients with cancer and key updates in the NCCN Guidelines and apply appropriate treatment and supportive care strategies to optimize patient education and care. 
•   Review issues related to the following topics: An Exploration of Oncology Professions Beyond Research and Clinical Practice; How to Optimize Systemic Therapy Outside of the Cancer Center: Best Practices for Managing Anticancer Therapies; The Art of Creating and Sustaining Interprofessional Teams to Provide Comprehensive Care Throughout the Patient Journey; Team-Based Management of Immunotherapy-Related Toxicities; and Management of Central Nervous System Metastases.

How to Optimize Systemic Therapy Outside of the Cancer Center: Best Practices for Managing Anticancer Therapies
•   Describe the challenges associated with the use of oral anticancer therapies.
•   Discuss the strategies that can be utilized to optimize the use oral anticancer therapies.
•   Identify the resources and requirements needed for the implementation of a treatment plan to improve the use of oral anticancer therapy in outpatient settings.

The Art of Creating and Sustaining Interprofessional Teams to Provide Comprehensive Care Throughout the Patient Journey
•   Describe the spectrum of physical, emotional and psychosocial effects of cancer and cancer treatment on patients and survivors.
•   Explain how various members of the interprofessional team can help support patients, survivors, and caregivers by providing education, managing side effects, and addressing psychosocial problems to maximize quality of life.
•   Discuss approaches to building and maintaining effective multidisciplinary, interprofessional teams to provide comprehensive care to patients with cancer and survivors.

Management of Central Nervous System Metastases
•   Describe advances in diagnosis and treatment of brain metastases.
•   Understand the evidence supporting stereotactic radiosurgery and whole brain radiation therapy for treatment of brain metastases, as well as potential effects on cognitive function and quality of life.
•   Identify emerging systemic therapy options for patients with brain metastases, including targeted therapies.

Team-Based Management of Immunotherapy-Related Toxicities
•   Describe the different classes of cancer immunotherapy (i.e., ICIs and CAR-T therapy), and how immunotherapy-related toxicities differ from those elicited by traditional chemotherapy.
•   Identify which organ systems are most commonly affected by immunotherapy-related toxicities and when disease specialist consultation may be warranted.
•   Discuss multidisciplinary strategies to facilitate early diagnosis and treatment of immunotherapy-related toxicities.

An Exploration of Oncology Professions Beyond Research and Clinical Practice 
•   Identify professional opportunities for employment that do not involve direct patient care.
•   Describe qualifications for various roles outside of the traditional clinical setting.
•   Identify ways in which trainees can supplement their professional development during fellowship for any potential future career path in oncology.

Additional information
AttachmentSize
PDF icon Program Details (agenda, accreditation, disclosures, & biographies)790.63 KB
PDF icon Session 1 - Optimize Systemic Therapy Outside of the Cancer Center2.66 MB
PDF icon Session 2 - The Art of Creating and Sustaining Interprofessional Teams1.86 MB
PDF icon Session 3 - Management of Central Nervous System Metastases3.87 MB
PDF icon Session 4 - Team-Based Management of Immunotherapy-Related Toxicities1.53 MB
PDF icon Session 5 - An Exploration of Oncology Professions404.81 KB
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Coherus BioSciences
  • Genentech, a member of the Roche Group
  • Gilead Sciences,Inc.
  • GSK
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Novartis
  • NOVOCURE

 
This activity is supported by an independent educational grant from Bristol Myers Squibb.

This educational activity is supported by a medical education grant from Exelixis, Inc.

This activity is supported by a grant from Pfizer Inc.

Course summary
Available credit: 
  • 5.00 AMA PRA Category 1 Credit™
  • 5.00 Participation
Course opens: 
03/29/2023
Course expires: 
08/31/2023
Event starts: 
03/30/2023 - 12:00pm EDT
Event ends: 
03/30/2023 - 6:15pm EDT
Cost:
$0.00
Add to calendar: 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty and Moderator Disclosures

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Gwen Darien
Susan E. Franco, RN, BSN, OCN
Wui-Jin Koh, MD
Yehoda M. Martei, MD, MSCE
Barbara L. McAneny, MD
Bryan J. Schneider, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Jonathan D. Cheng, MD
Bristol-Myers Squibb Company: Equity Interest/Stock Options; Salary 
Merck & Co., Inc.: Equity Interest/Stock Options

Robert L. Coleman, MD
AbbVie, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support; Honoraria; Scientific Advisor 
Caris Life Sciences: Scientific Advisor
Clovis Oncology: Grant/Research Support 
Eisai Inc.: Scientific Advisor
Genentech, Inc.: Grant/Research Support 
GlaxoSmithKline: Consulting Fee; Scientific Advisor
ImmunoGen, Inc.: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor 
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Novocure: Grant/Research Support; Scientific Advisor 
SeaGen: Grant/Research Support; Scientific Advisor

Crystal S. Denlinger, MD
Agios, Inc.: Grant/Research Support 
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support 
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support 
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Grant/Research Support 
Genmab: Grant/Research Support 
MacroGenics: Grant/Research Support 
MedImmune Inc: Grant/Research Support 
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support 
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support

Timothy Kubal, MD, MBA
Apellis Pharmaceuticals: Consulting Fee

L. Burt Nabors, MD
Chimerix: Scientific Advisor

Bianca D. Santomasso, MD, PhD
Bristol-Myers Squibb Company: Consulting Fee 
Gilead Sciences, Inc.: Consulting Fee
IN8BIO, Inc.: Scientific Advisor 
Incyte Corporation: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee 
Legend Biotech: Consulting Fee

B. Douglas Smith, MD
Bristol-Myers Squibb Company: Consulting Fee 
Celgene Corporation: Consulting Fee 
Celularity Inc.: Consulting Fee
Jubilant Pharma Limited: Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fee 
Pfizer Inc.: Consulting Fee
Servier Pharmaceuticals LLC: Consulting Fee

Yinghong (Mimi) Wang, MD, PhD 
AzurRx BioPharma: Consulting Fee 
Ilya Pharma AB: Consulting Fee 
MabQuest SA: Scientific Advisor 
Sanarentero, LLC: Consulting Fee
Sorriso Pharmaceuticals: Consulting Fee 
Springer: Royalty Income

NCCN Staff Disclosures

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Crystal S. Denlinger, MD
Agios, Inc.: Grant/Research Support 
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support 
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support 
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Grant/Research Support 
Genmab: Grant/Research Support 
MacroGenics: Grant/Research Support 
MedImmune Inc: Grant/Research Support 
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support 
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 5.00 AMA PRA Category 1 Credit™
  • 5.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Please log in with the same email address used for program registration.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing